AZIN1

AZIN1 is a central positive regulator of polyamine biosynthesis and cell proliferation that functions by binding and sequestering antizyme, thereby preventing antizyme-mediated proteasomal degradation of ornithine decarboxylase (ODC), cyclin D1, and c-Myc (PMID:23291631, PMID:39962590, PMID:40246846). ADAR1 p150 catalyzes A-to-I RNA editing of AZIN1 mRNA after splicing, introducing an S367G substitution that increases antizyme-binding affinity, enhances protein stability, and triggers cytoplasmic-to-nuclear translocation via interaction with an actin/myosin9 complex or DDX1, enabling nuclear functions including chromatin remodeling of hematopoietic regulators (PMID:37209819, PMID:36202978, PMID:34388251). Edited AZIN1 acts as a gain-of-function oncogene across multiple cancer types by stabilizing c-Myc to promote angiogenesis, conferring cancer stem-cell properties, driving immune evasion, and activating glycolysis and nicotinamide biosynthesis pathways beyond canonical polyamine production (PMID:35365616, PMID:29925690, PMID:38954486, PMID:40246846). AZIN1 also participates in anti-fibrotic signaling: a polyamine-independent splice variant suppresses fibrogenic markers in hepatic stellate cells, and AZIN1 overexpression antagonizes TGF-β/Smad3-driven renal fibrosis (PMID:21837750, PMID:23868013).

1. 2013 High

   The discovery that ADAR1-mediated A-to-I editing of AZIN1 produces an S367G substitution that alters protein conformation, localization, antizyme-binding affinity, and stability established AZIN1 RNA editing as a functionally consequential oncogenic event and defined the core biochemical mechanism by which edited AZIN1 neutralizes antizyme-mediated degradation of ODC and cyclin D1.

   Evidence Transcriptome sequencing, site-directed mutagenesis, Co-IP, subcellular fractionation, in vivo tumor models in hepatocellular carcinoma

   PMID:23291631

   Open questions at the time

   • The enzyme isoform responsible for AZIN1 editing (p110 vs. p150) and the timing relative to splicing were not resolved
   • Mechanism of nuclear translocation of edited AZIN1 was not identified
   • Whether edited AZIN1 has nuclear functions beyond antizyme sequestration was unknown
2. 2013 Medium

   Parallel work identified an AZIN1 splice variant (SV2) that suppresses fibrogenic markers through a polyamine-independent, antizyme-independent pathway, and showed that AZIN1 overexpression antagonizes TGF-β/Smad3 signaling in renal fibrosis, revealing non-canonical roles for AZIN1 outside polyamine regulation.

   Evidence Minigene splicing assays, shRNA knockdown, AZIN1 overexpression in hepatic stellate cells and kidney fibrosis models with in vivo gene delivery

   PMID:21837750 PMID:23868013

   Open questions at the time

   • The polyamine-independent mechanism of AZIN1 SV2 action on fibrogenic genes is undefined
   • Whether the anti-fibrotic splice variant and the edited form interact or compete is unknown
   • Findings are from single laboratories without independent replication
3. 2018 Medium

   Demonstrating that edited AZIN1 confers cancer stem-cell properties and enhanced metastatic potential in colorectal cancer extended the oncogenic editing paradigm beyond proliferation to stemness and invasion.

   Evidence Edited vs. wild-type AZIN1 expression in CRC cell lines, stemness assays, in vivo metastasis models, patient cohort analysis

   PMID:29925690

   Open questions at the time

   • Downstream transcriptional programs driven by edited AZIN1 in stem cells were not identified
   • Whether stem-cell phenotypes depend on nuclear AZIN1 or cytoplasmic antizyme inhibition was not distinguished
4. 2021 High

   Identification of DDX1 as a nuclear binding partner of edited AZIN1 in hematopoietic stem/progenitor cells, with consequent alteration of DDX1 chromatin distribution and hematopoietic gene expression, established a non-canonical nuclear mechanism for edited AZIN1 independent of polyamine biosynthesis.

   Evidence Co-IP/pulldown, subcellular fractionation, chromatin distribution assays, functional differentiation assays in sorted murine hematopoietic populations

   PMID:34388251

   Open questions at the time

   • Direct genomic targets of the AZIN1–DDX1 complex are not mapped
   • Whether DDX1-mediated chromatin remodeling also operates in cancer contexts is untested
5. 2022 Medium

   Proteomic identification of ACTA2, ACTG1, and myosin9 as editing-specific interactors of AZIN1 provided a molecular mechanism for the cytoplasmic-to-nuclear translocation of edited AZIN1, while parallel work showed that edited AZIN1 stabilizes c-Myc via OAZ2 to drive angiogenesis through IL-8 secretion.

   Evidence Pulldown/mass spectrometry for interaction profiling; c-Myc stability and IL-8 expression assays with OAZ2 manipulation; in vivo tumor angiogenesis models

   PMID:35365616 PMID:36202978

   Open questions at the time

   • Whether actin/myosin9 transport and DDX1 binding represent sequential or alternative nuclear import mechanisms is unresolved
   • The relative contribution of OAZ1 vs. OAZ2 in different tissues has not been systematically compared
   • Findings from single laboratories
6. 2023 High

   Genetic dissection using isoform-specific knockout mice proved that AZIN1 coding-site editing is catalyzed exclusively by cytoplasmic ADAR1 p150 acting on spliced mRNA, resolving the enzyme identity and substrate timing questions left open by the original editing discovery.

   Evidence Adar1 p110/Adar2 double KO mice, Adar1 p150 KO mice, interferon treatment, NES deletion mutants, pre-mRNA vs. mRNA editing quantification

   PMID:37209819

   Open questions at the time

   • The dsRNA structure formed by downstream exon that enables editing has not been structurally resolved
   • How inflammation-induced ADAR1 isoform switching quantitatively tunes editing levels remains incompletely characterized
7. 2024 High

   Metabolomic and genetic lock-in studies revealed that edited AZIN1 activates glycolysis and nicotinamide biosynthesis in addition to polyamine synthesis, broadening the metabolic scope of AZIN1 editing beyond the polyamine pathway and linking it to kidney injury recovery.

   Evidence Genetically modified human cell lines and knock-in mice locked in edited or uneditable AZIN1 states, metabolomics, RNA sequencing, murine endotoxemia model

   PMID:38954486

   Open questions at the time

   • The molecular mechanism by which AZIN1 engages glycolytic and NAD+ biosynthetic enzymes is unknown
   • Whether these metabolic effects operate through antizyme inhibition or a distinct mechanism is unresolved
8. 2025 Medium

   CRISPR knockout and knockdown studies in osteosarcoma and medulloblastoma demonstrated that AZIN1 sustains MYC protein levels and promotes cell cycle progression, immune evasion, and tumor aggressiveness through polyamine-dependent antizyme inhibition, consolidating its role as a druggable oncogenic node.

   Evidence CRISPR-Cas9 KO with orthotopic mouse models; siRNA/shRNA knockdown with TCR-engineered T-cell cytotoxicity assays and polyamine depletion experiments

   PMID:39962590 PMID:40246846

   Open questions at the time

   • Whether therapeutic targeting of AZIN1 is feasible without disrupting normal polyamine homeostasis is untested
   • The mechanism by which AZIN1/polyamines regulate HLA expression and immune evasion is not defined
   • Findings are from single laboratories

• Key unresolved questions include the structural basis of the S367G conformational change, whether the nuclear functions of edited AZIN1 (DDX1 interaction, chromatin remodeling) operate through antizyme-dependent or -independent mechanisms, and whether AZIN1 editing can be therapeutically modulated without disrupting normal ADAR1 function.
• No crystal or cryo-EM structure of wild-type or edited AZIN1 exists
• The relationship between antizyme-dependent and antizyme-independent nuclear functions has not been dissected
• No pharmacological tool compounds targeting AZIN1 or its editing have been reported